|
Market Closed -
Nasdaq
16:00:00 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 245.87 USD | +0.03% |
|
-0.38% | +44.63% |
| 09-11 | Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says | MT |
| 09-11 | UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- JAZZ Stock
- Consensus Jazz Pharmaceuticals plc
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
